eliem therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. headquartered in seattle with r&d primarily in cambridge, uk, eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. these conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. at its core, the eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. eliem is a publicly traded company (nasdaq: elym) read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/
Company profile
Ticker
ELYM
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
832273741
ELYM stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
11 Apr 24
8-K
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
11 Apr 24
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Other Events
18 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
8-K
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
11 May 23
Latest ownership filings
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Apr 24
4
Valerie Morisset
8 Apr 24
4
Emily Pimblett
20 Mar 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
18 Mar 24
4
Valerie Morisset
4 Mar 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
17 Nov 23
SC 13D/A
AI ETI LLC
13 Nov 23
4
Peter Kolchinsky
22 May 23
4
Simon Tate
22 May 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 57.35 mm | 57.35 mm | 57.35 mm | 57.35 mm | 57.35 mm | 57.35 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.67 mm | 3.73 mm | (no burn) | 2.34 mm |
Cash used (since last report) | n/a | n/a | 11.36 mm | 25.38 mm | n/a | 15.95 mm |
Cash remaining | n/a | n/a | 46.00 mm | 31.98 mm | n/a | 41.40 mm |
Runway (months of cash) | n/a | n/a | 27.6 | 8.6 | n/a | 17.7 |
Institutional ownership, Q3 2023
99.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 6 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 44.04 bn |
Total shares | 27.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ra Capital Management | 13.15 mm | $34.59 bn |
Ai Eti | 5.01 mm | $13.58 mm |
Intermediate Capital | 2.00 mm | $0.00 |
ICG Life Sciences SCSp | 2.00 mm | $20.95 mm |
BML Capital Management | 1.94 mm | $5.10 bn |
BML Investment Partners | 1.72 mm | $4.78 mm |
Driehaus Capital Management | 811.68 k | $2.13 bn |
Vanguard | 309.82 k | $814.83 mm |
Silverarc Capital Management | 121.11 k | $318.52 mm |
Atom Investors | 78.89 k | $207.47 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Valerie Morisset | Common Stock | Option exercise | Acquire M | No | No | 0.0002 | 17,847 | 3.57 | 505,307 |
5 Apr 24 | Valerie Morisset | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.0002 | 17,847 | 3.57 | 28,046 |
18 Mar 24 | Emily Pimblett | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 40,000 | 0.00 | 40,000 |
20 Sep 23 | Valerie Morisset | Common Stock | Option exercise | Acquire M | No | No | 0.0002 | 15,297 | 3.06 | 487,460 |
20 Sep 23 | Valerie Morisset | Common Stock | Option exercise | Acquire M | No | No | 0.002 | 5,431 | 10.86 | 472,163 |
20 Sep 23 | Valerie Morisset | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.0002 | 15,297 | 3.06 | 45,893 |
20 Sep 23 | Valerie Morisset | Stock Option Common Stock | Option exercise | Dispose M | No | No | 0.002 | 5,431 | 10.86 | 0 |
18 May 23 | Andrew David Levin | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 10,000 | 30.00 k | 10,000 |
18 May 23 | Adam Joseph Rosenberg | Stock Option Common Stock | Grant | Acquire A | No | No | 3 | 10,000 | 30.00 k | 10,000 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Apr 24
Nasdaq Jumps 250 Points; Crude Oil Down 1%
11 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
11 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
Press releases
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN
22 Apr 24
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the Firm
15 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, ALPN, ELYM, JBT
13 Apr 24
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
11 Apr 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODN
11 Apr 24